Impact of first‐line infliximab on the pharmacokinetics of second‐line vedolizumab in inflammatory bowel diseases

Very little is known about the impact of the wash-out period on the pharmacokinetics of a second-line biologic.The objective of this article is to explore the impact of two different wash-out periods on the pharmacokinetics of vedolizumab and infliximab.Patients switching from infliximab to vedolizumab were retrospectively identified. The population was divided into two groups according to wash-out period: <6 weeks or >6 weeks. Vedolizumab and...